Embecta Corp.

EMBC

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001872789

C/D

on the C/D boundary of 367 graded peers in healthcare

rank 228 of 367; percentile 62.0; sampling error 2.5 points; lower is stronger

A B C D E


C/D, the tortoise



Scoreboard


Profitability	B	percentile 23.2
Solvency	D	percentile 70.4
Growth and financing	D	percentile 63.5
Reliability	0.91 AUC	filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets	total assets $1.1B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	late filer	not computable: distress
Inputs computable	10 of 14	
Graded from	filings received through Nov 25, 2025	356 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	$6.45	2026-11-13; market equity $365.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Nov 25, 2025

Embecta Corp. (also referred to herein as "Embecta") is a leading global medical device company, primarily focused on providing solutions to improve the health and well-being of people living with diabetes. All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the context. Building on our 100-year centennial, we believe that our products have become one of the most widely recognized and respected brands in diabetes management throughout the world.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 23.2						
Gross profitability	62.0%	32.3%		15.1	365	2025-09-30
Return on invested capital	31.1%	9.3%		6.8	74	2025-09-30
Accruals ratio	(8.1%)	(6.6%)		47.7	799	2025-09-30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 4						
Solvency, sleeve percentile 70.4						
Twelve-month failure probability	not computable	0.08%				
liabilities and a nearby cover-page share count are required at 2026-06-30						
Altman Z double-prime	not computable	(0.31)				
one or more required annual facts are missing						
Net debt to EBITDA	4.15x	1.82x		75.7	75	2025-09-30
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	2.41x	2.96x		65.0	825	2025-09-30
Growth and financing, sleeve percentile 63.5						
Revenue growth, three-year compound	(1.5%)	10.1%		74.6	411	2025-09-30
Free cash flow growth, three-year compound	(22.3%)	11.0%		89.4	95	2025-09-30
Reinvestment rate	(28.6%)	37.1%		81.6	104	2025-09-30
Asset growth, three years	0.1%	2.3%		51.4	693	2025-09-30
Net share issuance, one year	0.7%	2.4%		20.6	627	2025-11-18


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
223	Rocket Pharmaceuticals, Inc. (RCKT)	60.7	C/D	degenerate inputs
224	Tango Therapeutics, Inc. (TNGX)	60.9	C/D	dilution
225	Teva Pharmaceutical Industries Ltd. (TEVA)	61.2	C/D	
226	Akebia Therapeutics, Inc. (AKBA)	61.5	C/D	fortress balance sheet
227	Amylyx Pharmaceuticals, Inc. (AMLX)	61.7	C/D	degenerate inputs
228	Embecta Corp. (EMBC)	62.0	C/D	late filer
229	Lenz Therapeutics, Inc. (LENZ)	62.3	C/D	short runway
230	Biogen Inc. (BIIB)	62.6	D	
231	Beam Therapeutics Inc. (BEAM)	62.8	D	
232	AbbVie Inc. (ABBV)	63.1	D	
233	Perspective Therapeutics, Inc. (CATX)	63.4	D	dilution, short runway, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(56.3%)	(1.5%)	12
Distance from 52-week high	(55.9%)	(32.0%)	26
EBIT to enterprise value	15.6%	(1.8%)	94
Free cash flow yield	49.8%	(1.0%)	99
Book value to price	(1.67)	0.29	1
Sales to price	2.95	0.29	94
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	(0.99)	(0.18)	12

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-09-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$214.7M
Operating cash flow, four quarters	$174.1M
Months of runway	not finite
Days since last periodic filing	101 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	$5.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$676.8M	2025-09-30	2025-11-25	10-K	25-000036
2	assets	us-gaap:Assets	$1.1B	2025-09-30	2025-11-25	10-K	25-000036
3	operating income	us-gaap:OperatingIncomeLoss	$242.1M	2025-09-30	2025-11-25	10-K	25-000036
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$136.3M	2025-09-30	2025-11-25	10-K	25-000036
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$40.9M	2025-09-30	2025-11-25	10-K	25-000036
6	total debt	us-gaap:LongTermDebt	$1.4B	2025-09-30	2025-11-25	10-K	25-000036
7	book equity	us-gaap:StockholdersEquity	-$650.6M	2025-09-30	2025-11-25	10-K	25-000036
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$225.5M	2025-09-30	2025-11-25	10-K	25-000036
9	total debt	us-gaap:LongTermDebt	$1.6B	2024-09-30	2024-12-11	10-K	24-000037
10	book equity	us-gaap:StockholdersEquity	-$738.3M	2024-09-30	2025-11-25	10-K	25-000036
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$267.5M	2024-09-30	2025-11-25	10-K	25-000036
12	net income	us-gaap:NetIncomeLoss	$95.4M	2025-09-30	2025-11-25	10-K	25-000036
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$191.7M	2025-09-30	2025-11-25	10-K	25-000036
14	assets	us-gaap:Assets	$1.3B	2024-09-30	2025-11-25	10-K	25-000036
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$40.7M	2025-09-30	2025-11-25	10-K	25-000036
16	current assets	us-gaap:AssetsCurrent	$631.4M	2025-09-30	2025-11-25	10-K	25-000036
17	current liabilities	us-gaap:LiabilitiesCurrent	$261.5M	2025-09-30	2025-11-25	10-K	25-000036
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2025-09-30	2025-11-25	10-K	25-000036

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2024-09-30	2025-11-25	10-K	25-000036
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2023-09-30	2025-11-25	10-K	25-000036
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2022-09-30	2024-12-11	10-K	24-000037
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9.3M	2025-09-30	2025-11-25	10-K	25-000036
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$35.7M	2024-09-30	2025-11-25	10-K	25-000036
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$15.8M	2024-09-30	2025-11-25	10-K	25-000036
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$67.7M	2023-09-30	2025-11-25	10-K	25-000036
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$26.5M	2023-09-30	2025-11-25	10-K	25-000036
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$412.2M	2022-09-30	2024-12-11	10-K	24-000037
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$23.6M	2022-09-30	2024-12-11	10-K	24-000037
29	current assets	us-gaap:AssetsCurrent	$761.0M	2024-09-30	2025-11-25	10-K	25-000036
30	current liabilities	us-gaap:LiabilitiesCurrent	$374.0M	2024-09-30	2025-11-25	10-K	25-000036
31	assets	us-gaap:Assets	$1.2B	2023-09-30	2024-12-11	10-K	24-000037
32	assets	us-gaap:Assets	$1.1B	2022-09-30	2023-11-29	10-K	23-000031
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	58,512,841	2025-11-18	2025-11-25	10-K	25-000036
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	58,130,561	2024-11-29	2024-12-11	10-K	24-000037

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.